David R. Snead

2.2k total citations · 1 hit paper
38 papers, 1.7k citations indexed

About

David R. Snead is a scholar working on Molecular Biology, Organic Chemistry and Biomedical Engineering. According to data from OpenAlex, David R. Snead has authored 38 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 18 papers in Organic Chemistry and 17 papers in Biomedical Engineering. Recurrent topics in David R. Snead's work include Innovative Microfluidic and Catalytic Techniques Innovation (16 papers), Chemical Synthesis and Analysis (11 papers) and Synthetic Organic Chemistry Methods (7 papers). David R. Snead is often cited by papers focused on Innovative Microfluidic and Catalytic Techniques Innovation (16 papers), Chemical Synthesis and Analysis (11 papers) and Synthetic Organic Chemistry Methods (7 papers). David R. Snead collaborates with scholars based in United States, Germany and United Kingdom. David R. Snead's co-authors include Timothy F. Jamison, Andrea Adamo, Shin Yee Wong, Ping Zhang, Jean‐Christophe M. Monbaliu, Eve Revalor, Klavs F. Jensen, Nopphon Weeranoppanant, Mohsen Behnam and Jie Chen and has published in prestigious journals such as Science, Angewandte Chemie International Edition and Chemical Communications.

In The Last Decade

David R. Snead

38 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system

2016 725 citations Timothy F. Jamison, David R. Snead et al. profile →

Peers

Countries citing papers authored by David R. Snead

Since Specialization

Citations

This map shows the geographic impact of David R. Snead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Snead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Snead more than expected).

Fields of papers citing papers by David R. Snead

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Snead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Snead. The network helps show where David R. Snead may publish in the future.

Co-authorship network of co-authors of David R. Snead

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Snead. A scholar is included among the top collaborators of David R. Snead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Snead. David R. Snead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849) 2024 ·Organic Process Research & Development ·Thomas Scattolin, (unknown), David R. Snead, Zhichao Lu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cheng‐yi Chen	2
2	Access to Cyclopropanol via Supply-Centered Synthesis 2024 ·Organic Process Research & Development ·David R. Snead, Yang Wang, Shuqiang Liu, (unknown)	3
3	Development of Adagrasib’s Commercial Manufacturing Route 2023 ·Organic Process Research & Development ·David R. Snead, (unknown), Thomas Scattolin, (unknown), Michał Achmatowicz, Duane E. Rudisill, (unknown), (unknown), (unknown), (unknown), (unknown), Wei Liu, (unknown), (unknown), Cheng‐yi Chen	13
4	Practical and Scalable Two-Step Process for 6-(2-Fluoro-4-nitrophenyl)-2-oxa-6-azaspiro[3.3]heptane: A Key Intermediate of the Potent Antibiotic Drug Candidate TBI-223 2023 ·Organic Process Research & Development ·Flávio S. P. Cardoso, (unknown), Ryan C. Nelson, (unknown), (unknown), (unknown), (unknown), Anthony J. Arduengo, Justina M. Burns, (unknown), David R. Snead, Fengrui Qu, (unknown), Saeed Ahmad, (unknown), Joshua D. Sieber, Kai Donsbach	4
5	Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol 2023 ·Organic Process Research & Development ·(unknown), (unknown), Flávio S. P. Cardoso, David R. Snead, Ryan C. Nelson, Kai Donsbach, B. Frank Gupton, Till Opatz	5
6	Scalable Atroposelective Synthesis of MRTX1719: An Inhibitor of the PRMT5/MTA Complex 2023 ·Organic Process Research & Development ·Michał Achmatowicz, Thomas Scattolin, David R. Snead, (unknown), (unknown), Chen Xie, (unknown), Cheng‐yi Chen	7
7	Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block 2023 ·Organic Process Research & Development ·David R. Snead, (unknown), Cheng‐yi Chen	3
8	Facile and Scalable Methodology for the Pyrrolo[2,1- f ][1,2,4]triazine of Remdesivir 2022 ·Organic Process Research & Development ·Sarabindu Roy, (unknown), (unknown), Gopal Sirasani, (unknown), Jack D. Brown, Joseph D. Armstrong, Rodger W. Stringham, B. Frank Gupton, Chris H. Senanayake, David R. Snead	8
9	A Practical and Economical Route to (S)-Glycidyl Pivalate 2022 ·SynOpen ·Flávio S. P. Cardoso, David R. Snead, (unknown), Le Chang, Dan Chen, (unknown), Raymond N. Dominey, Daniel W. Cook, Justina M. Burns, Rodger W. Stringham	1
10	Diastereoselectivity is in the Details: Minor Changes Yield Major Improvements to the Synthesis of Bedaquiline** 2022 ·Chemistry - A European Journal ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David R. Snead, Ryan C. Nelson, Till Opatz, Timothy F. Jamison	5
11	Development of a Practical Synthesis of the 8-FDC Fragment of OPC-167832 2022 ·ACS Omega ·(unknown), (unknown), (unknown), (unknown), (unknown), Justina M. Burns, (unknown), Daniel W. Cook, Rodger W. Stringham, Ryan C. Nelson, Saeed Ahmad, B. Frank Gupton, David R. Snead, D. Tyler McQuade, Rajappa Vaidyanathan, Kai Donsbach, Joshua D. Sieber	2
12	Toward a Practical, Two-Step Process for Molnupiravir: Direct Hydroxamination of Cytidine Followed by Selective Esterification 2021 ·Organic Process Research & Development ·(unknown), (unknown), Saeed Ahmad, (unknown), Flávio S. P. Cardoso, Justina M. Burns, Daniel W. Cook, Rodger W. Stringham, David R. Snead	30
13	Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine 2021 ·ACS Omega ·(unknown), (unknown), Chris H. Senanayake, Joseph D. Armstrong, (unknown), Sarabindu Roy, Saeed Ahmad, David R. Snead, Timothy F. Jamison	33
14	Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis 2021 ·Organic Process Research & Development ·(unknown), (unknown), (unknown), David R. Snead, (unknown), Timothy F. Jamison, Chris H. Senanayake, (unknown), Sarabindu Roy, Gopal Sirasani, B. Frank Gupton, Justina M. Burns, Daniel W. Cook, Rodger W. Stringham, Saeed Ahmad, (unknown)	11
15	A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2 2020 ·Synlett ·David R. Snead, (unknown), (unknown), Jeffrey S. Noble, Timothy F. Jamison, B. Frank Gupton	19
16	An Efficient Synthesis of Tenofovir (PMPA): A Key Intermediate Leading to Tenofovir-Based HIV Medicines 2020 ·Organic Process Research & Development ·(unknown), (unknown), (unknown), (unknown), (unknown), Flávio S. P. Cardoso, (unknown), (unknown), Anthony J. Arduengo, Till Opatz, David R. Snead, Rodger W. Stringham, D. Tyler McQuade, B. Frank Gupton	14
17	A concise route to MK-4482 (EIDD-2801) from cytidine 2020 ·Chemical Communications ·(unknown), (unknown), (unknown), (unknown), Flávio S. P. Cardoso, (unknown), (unknown), Till Opatz, Timothy F. Jamison, (unknown), David R. Snead	34
18	A Continuous Flow Sulfuryl Chloride-Based Reaction—Synthesis of a Key Intermediate in a New Route toward Emtricitabine and Lamivudine 2020 ·Organic Process Research & Development ·(unknown), (unknown), David R. Snead, D. Tyler McQuade	6
19	Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis 2020 ·Organic Letters ·(unknown), Flávio S. P. Cardoso, (unknown), (unknown), Daniel W. Cook, Justina M. Burns, Rodger W. Stringham, Joshua D. Sieber, B. Frank Gupton, David R. Snead	29
20	Synthesis of an Oxathiolane Drug Substance Intermediate Guided by Constraint-Driven Innovation 2020 ·Organic Process Research & Development ·(unknown), David R. Snead, Justina M. Burns, Rodger W. Stringham, B. Frank Gupton, D. Tyler McQuade	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact